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Abstract 
The aim of this work is to study the influence of formulation parameters 
in the preparation of controlled release floating matrix tablets of 
Cefixime. A 32 full factorial experiment was designed to study the 
effects of the ratio of HPMC K4M to HPMC K100 LV (X1) and content 
of citric acid (X2). The results of factorial design indicated that ratio of 
HPMC K4M to HPMC K100LV had dominant role on drug release from 
floating matrix tablets compared to citric acid, although the presence of 
later component in formulation with optimum concentration is essential 
to improve the drug release of hydrophobic molecules of drug. The 
linear regression analysis and model fitting showed that all these 
formulations followed Korsmeyer and Peppas model, which had a 
higher value of correlation coefficient (r). Three dimensional response 
graphs were presented to visualize the effect of independent variables on 
the chosen response. For the development of controlled release dosage 
form for poorly soluble drug like Cefixime trihydrate, polymer blends of 
different viscosity grade of HPMC and presence of citric acid appears 
necessary, which imparts hydrophilic environment and to increase drug 
release, respectively. 
Keywords: Cefixime, HPMC K 100 LV, HPMC K4M, HPMC K15M 
and HPMC K100M 
Introduction 
Retention of dosage forms in the stomach 
prolongs overall gastrointestinal transit time and 
improves the oral bioavailability of the drugs that 
are having site specific absorption from the 
stomach or upper part of the small intestine. 
Therefore different approaches have been 
proposed to retain the dosage form in the stomach 
including bioadhesive systems, swelling and 
expanding systems, floating systems, and delayed 
gastric emptying devices. the principle of buoyant 
preparation offers a simple and practical 
approach to achieve increased gastric residence 
time for the dosage form and sustain drug release. 
Cefixime is orally active third generation 
cephalosporin active against enterobacteriaceae, 
Haemofilia influenzae, Streptococcus pyogenes,  
 
Streptococcus pneumoniae, Moraxella, E. coli, 
Protease, Neisseria gonorrhea and is resistant to 
many b- lactamases. The absolute bioavailability 
of all newer oral cephalosporin is below 50-60%, 
which suggests an absorption mechanism through 
the mucosa with limited capacity. The biological 
half life of Cefixime is 3.0 ± 0.4 and dosing of 
Cefixime is 200 mg twice a day for 7-10 days.(1-2) 
Considering the wide range of activity of 
Cefixime, the objective of this study was to 
decrease the dose frequency and increase the 
speed of recovery from the indications by 
increasing the rate of bacterial killing and thereby 
increasing patient compliance. Aim of present 
work is to develop, optimize and characterize 
gastroretentive tablet of Cefixime to reduce the 
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frequency of dosing and to increase effectiveness 
of the drug by localization at the site of action, 
reducing the dose required, or providing the 
uniform drug delivery and patient compliance. In 
context of the above principles, a strong need is 
felt to develop a dosage form that would increase 
in the efficiency of the drug, providing sustains 
action. Thus in the present investigation, a 
systematic approach will be applied for the 
formulation and development of gastroretentive 
Cefixime dosage forms. In context to above 
intention, following criteria were aimed to 
achieve. 
• Floating lag time of drug delivery system 
should be less than 15 min. 
• Total floating time of drug delivery 
system should be approx. 12 hours. 
• The first hour drug release should be 
around 32 %, which is calculated based 
on the pharmacokinetic parameters of 
Cefixime.  
More than 90% of drug should be released within 
12 hours. The gastroretentive drug delivery 
system can be retained in the stomach and assists 
in improving the oral sustained delivery of drugs 
that have and absorption window in a particular 
region of the GI tract. These systems help in 
continuously releasing the drug before it reaches 
the absorption window, thus ensuring optimal 
bioavailability. Several approaches are currently 
used to prolong gastric retention time. These 
include floating drug delivery systems, swelling 
and expanding systems, polymeric bioadhesive 
systems, high –density systems and other delayed 
gastric-emptying devices.(3) The principle of 
buoyant preparation offers a simple and practical 
approach to achieve increased gastric residence 
time for dosage form and sustained drug release. 
The present investigation describes the 
formulation development of an intragastric 
floating drug delivery system of Cefixime. 
 
Materials and Methods 
Materials 
Cefixime was received as generous gift from 
Lincoln Pharmaceuticals Limited, Ahmedabad, 
India, HPMC K100LV, HPMCK4M, 
HPMCK15M and HPMCK100M were received 
from Zydus-Cadila Healthcare Limited, 
Ahmedabad, India, Sodium bicarbonate, citric 
acid and magnesium Stearate were received from 
S.D. Fine-Chem. Limited, India. All other 
chemicals used were of analytical reagent grade, 
available commercially and used as such without 
further processing. 
 
Methods 
Preparation of Cefixime trihydrate floating 
tablets: 
Tablets were prepared by direct compression 
technique. Cefixime trihydrate (479 mg 
equivalent to 400 mg of Cefixime anhydrous) 
was mixed with required components except 
Magnesium Stearate by geometric mixing. The 
powder blend was then lubricated with 
Magnesium Stearate (1%w/w) and manually 
compressed on single punch tablet machine using 
5 mm standard round punch. The lactose being 
water soluble filler was used to maintain constant 
tablet weight as well as to counter balance the 
poor water solubility of drug. The tablets were 
compressed to obtain hardness in a range of 5-7 
Kg/cm2. 
 
Factorial Design 
A 32 randomized full factorial design was utilized 
in the present study for development of dosage 
form. In this design two factors were evaluated, 
each at three levels, and experimental trials were 
performed at all nine possible combinations. The 
ratio of HPMC K4M to HPMC K100LV (X1) and 
the amount of citric acid (X2) were selected as 
independent variables. The time required for 50% 
of drug release (t50%), percentage drug release at 
12 hr (Q12), release rate constant (k) and 
diffusion exponent (n) were selected as 
dependent variables. Content of polymer blend 
was kept constant at 12.85 % of total tablet 
weight. The ratio of HPMC K4M and HPMC 
K100 LV was evaluated at 80:20, 70:30 and 
60:40 while the content of citric acid was 
evaluated at 0%, 1% and 2% of total tablet 
weight. The experimental design with 
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corresponding formulations is outlined in Table 
1.  
 
Table 1. Formulation of factorial design batches 
 
Batch 
code 
Coded level Actual value(mg) 
X1 X2 X1 X2 
A10 
A11 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
+1 
+1 
+1 
0 
0 
0 
-1 
-1 
-1 
+1 
0 
-1 
+1 
0 
-1 
+1 
0 
-1 
54:36 
54:36 
54:36 
63:27 
63:27 
63:27 
72:18 
72:18 
72:18 
14 
7 
0 
14 
7 
0 
14 
7 
0 
X1 is ratio of HPMC K4M: HPMC K100 LV and 
X2 is amount of citric acid. All batches contained 
479 mg Cefixime trihydrate [equivalent to 400 mg 
of Cefixime (Anhydrous)], 50 mg sodium 
bicarbonate, 12.85 % of polymer blends, 1% of 
magnesium stearate and quantity sufficient of 
lactose. 
 
 
Table 2. Results of evaluation of tablets for 
factorial design batches  
 
 
Batch 
Code 
Assay 
(%) 
(n=20) 
Average 
weight 
(mg)(n=20) 
Friab- 
ility 
(%) 
Buoyancy 
Characteristics 
(n=3) 
FLT 
(sec) 
TFT 
(hr) 
A10 
A11 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
98.85 
98.36 
100.35 
100.86 
99.90 
101.28 
102.39 
100.29 
101.86 
700 (2.3) 
698 (2.8) 
700 (3.0) 
699 (2.5) 
699 (1.8) 
700 (2.2) 
700 (3.0) 
700 (1.7) 
699 (1.4) 
0.48 
0.54 
0.49 
0.56 
0.65 
0.64 
0.52 
0.47 
0.37 
60 (3) 
55 (5) 
65 (2) 
80 (3) 
92 (3) 
100 (3) 
85 (3) 
98 (3) 
118 (3) 
>12 
~8 
>12 
>12 
>12 
>12 
>12 
>12 
>12 
Value in parenthesis indicates standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Response surface plots for influence of ratio 
of HPMC K4M to HPMC  K100LV (X1) and content 
of citric acid (X2) on (a) t50% 
 
 
 
Table 3. Results of dependent variables for 
factorial design batches 
 
Batch 
Code 
t50% 
(min) 
Q12 
(%) 
Release 
rate 
constant(k) 
Diffusional 
release 
exponent(n) 
A10 
A11 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
100 
45 
110 
220 
185 
235 
310 
230 
440 
94.80 
109.19 
90.67 
79.19 
89.04 
73.98 
72.02 
80.09 
66.12 
40.93 
60.24 
42.29 
31.29 
26.41 
25.75 
26.60 
25.07 
20.39 
0.309 
0.242 
0.307 
0.364 
0.490 
0.439 
0.388 
0.466 
0.459 
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Table 4. Multiple regression analysis for dependent variables 
 
Parameters Coefficient   of regression parameters 
b0 b1 b2 b12 b11 b22 r2 P 
t50% 
Q12 
k 
n 
58.33 
89.61 
31.84 
0.45 
20.83 
12.74 
11.90 
-0.076 
25.83 
2.54 
1.73* 
-0.024* 
30.00* 
-0.44* 
-1.89* 
0.018* 
-7.50* 
4.74 
8.10* 
-0.069* 
82.50* 
-13.31 
-6.03* 
-0.022* 
0.960 
0.992 
0.870 
0.847 
0.030 
0.0022 
0.045 
0.040 
* Indicate the value is  insignificant at P = 0.05 
 
 
 
 
Table 5.  Results of ANOVA for dependent variables 
 
Parameters Parameters DF SS MS F Significance 
F 
t50% 
 
 
Q12 
 
 
k 
 
 
n 
Regression 
Residual 
Total 
Regression 
Residual 
Total 
Regression 
Residual 
Total 
Regression 
Residual 
Total 
5 
3 
8 
5 
3 
8 
5 
3 
8 
5 
3 
8 
108950 
5016.67 
113950 
1412.43 
10.59 
1423.02  
1086.07 
166.48 
1252.55 
0.050 
0.009 
0.059 
21786.67 
1672.22 
 
282.49 
3.53 
 
217.21 
55.49 
 
0.0160 
0.0037 
 
13.03 
 
 
80.02 
 
 
3.91 
 
 
3.34  
0.030 
 
 
0.0022 
 
 
0.045 
 
 
0.040 
 
DF is degree of freedom, SS is sum of square, MS is mean sum of square and F is Fischer’s 
ratio. 
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Table 6.   Results of Tukey test performed using two way ANOVA 
 
Response Comparison 
for levels 
P 
Ratio of  HPMC K4 M 
to HPMC K100LV(X1) 
Content of citric acid 
(X2) 
t50% 
 
 
Q12 
 
 
k 
 
 
 
n 
 
-1 Vs 1 
-1 Vs 0 
0  Vs 1 
-1 Vs 1 
-1 Vs 0 
0  Vs 1 
-1 Vs 1 
-1 Vs 0 
0  Vs 1 
-1 Vs 1 
-1 Vs 0 
0  Vs 1 
0.013 
0.143 
0.084 
0.003 
0.102 
0.014 
0.014 
0.031 
0.591 
0.044 
0.765 
0.083  
- 
- 
- 
0.557 
0.013 
0.028 
- 
- 
- 
- 
- 
- 
 
 
 
 
Characterization of the Microspheres 
Drug content and physical evaluation: 
Compressed tablets were evaluated for assay, 
weight variation(4) and friability(5) according USP 
28. For assay, the 20 tablets were crushed and the 
powder equivalent of 400 mg of drug was 
transferred to 1000 ml of 0.1 N HCl in volumetric 
flask. The solution was analyzed at 285 nm using 
double beam UV/Visible spectrophotometer after 
suitable dilution. The content of drug was 
calculated from calibration curve. The results 
shown in Table 2. 
 
 
In vitro buoyancy study: 
The in vitro buoyancy was characterized by 
floating lag time (FLG) and total floating 
time(TFT).The test was performed using USP 24 
type II paddle apparatus using 900 ml of 0.1 N 
HCl at 100 rpm at 37 ± 0.5oC. The time required 
for tablet to rise to surface of dissolution medium 
and duration of time the tablet constantly float on 
dissolution medium were noted as FLG and TFT 
, respectively (n=3).(6) 
 
Response Surface Analysis: 
A statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the 
response (Equation 1). 
 
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X1X1 + 
b22X2X2  ------------- (1) 
 
Where Y is the dependent variable, b0 is the 
arithmetic mean response of the 9 runs.   And bi is 
the estimated coefficients for the factor Xi. The 
main effect (X1 and X2) represents the average 
result of changing one factor at a time form its 
low to high value. The interaction term(X1X2) 
shows how the response changes when two 
factors are change simultaneously. The 
polynomial terms (X1X1, X2X2) are included to 
investigate nonlinearity. The reduced equation, an 
equation containing only statistically significant 
terms, is then used for drawing response surface 
plots to visualize the impact of changing 
variables at a glance. The optimum point may be 
identified from the plot and replicate trials may 
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be run to verify the prediction of optimum 
response. To demonstrate graphically the 
influence of each factor on responses, the 
response surface plots were generated using 
Sigma Plot software (Sigma Plot software 11.0, 
SPSS, USA). The response surface plots for 
factorial are depicted as Figure 1-4. The value of 
P< 0.05 was considered to be significant. 
 
 
 
Figure 2: Response surface plots for influence of 
ratio of HPMC K4M to HPMC K100LV (X1) and 
content of citric acid (X2) on (a) Q12 
 
 
 
Figure 3: Response surface plots for influence of 
ratio of HPMC K4M to HPMC K100LV (X1) and 
content of citric acid (X2) on (a) k 
 
 
 
 
 
Figure 4: Response surface plots for influence of 
ratio of HPMC K4M to HPMC K100LV (X1) and 
content of citric acid (X2) on (a) n 
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Figure 5: Dissolution profiles of tablets for 
factorial design batches 
 
In Vitro Drug Release 
The in vitro drug release was performed using 
USP 24 type II paddle apparatus using 900 ml of 
0.1 N HCl at 100 rpm at 37+ 0.5o C. The samples 
were withdrawn at predetermined time intervals 
for period of 12 hr and replaced with the fresh 
medium. The samples were filtered through 0.45 
µm membrane filter, suitably diluted and 
  -1.00
  -0.50
  0.00
  0.50
  1.00
-1.00  
-0.50  
0.00  
0.50  
1.00  
0.24  
0.3025  
0.365  
0.4275  
0.49  
 
 
Di
ffu
sio
n 
Ex
po
n
en
t ( 
n) 
 
  X1  
  X2  
  -1.00
  -0.50
  0.00
  0.50
  1.00
-1.00  
-0.50  
0.00  
0.50  
1.00  
18  
28.75  
39.5  
50.25  
61  
 
 
Ra
te
 
Co
n
st
.
 
K 
 
 
  X1    X2  
  -1.00
  -0.50
  0.00
  0.50
  1.00
-1.00  
-0.50  
0.00  
0.50  
1.00  
65  
76.25  
87.5  
98.75  
110  
 
 
Q1
2 
 
  X1    X2  
Baimark et al. International Journal of Drug Delivery 3 (2010) 94-99 
 
 
 
531 
analyzed at 285 nm using double beam 
UV/Visible spectrophotometer. The content of 
drug was calculated using calibration curve. 
Results were expressed as mean (± SD) of 3 
experiments. 
 
Statistical Analysis  
The statistical analysis of the factorial design 
batches were performed by multiple regression 
analysis using Microsoft Excel®. The results of 
multiple regression analysis for factorial design 
batches are depicted in Table 4. To evaluate 
contribution of each factor with different levels 
on responses, two way analysis of variance 
(ANOVA) followed by Tukey test was performed 
using Sigma Stat software (Sigma Stat 3.0, SPSS, 
USA). The results of ANOVA for factorial 
design batches are depicted in Table 5. The 
results of Tukey test are depicted in Table 6. To 
demonstrate graphically the influence of each 
factor on responses, the response surface plots 
were generated using Sigma Plot software (Sigma 
Plot software 11.0, SPSS, USA). The value of P< 
0.05 was considered to be significant. 
 
To evaluate and comparison of dissolution 
profiles, the dissolution profiles were analyzed 
using similarity factor f2 .The equation for 
calculating f2 is given below. Similarity factor f2: 
 
n 
f2 = 50 log {[1+1/n Σ Wt (Rt - Tt)-0.5 x 
100} 
t=1 
 
Where, n is numbers of dissolution time point, Wt 
is optional weight factor, Rt, is reference 
dissolution point at time t and Tt is test 
dissolution point at time t. The f2 value between 
50 and 100 suggests that the dissolution profiles 
are similar. The f2 value of 100 suggests that the 
test and reference profiles are identical and as the 
value becomes smaller, the dissimilarity between 
releases profile increases10, 11. 
 
Stability Study of the Optimized Batch 
In order to determine the change in performance 
of dosage from on storage, stability study of 
batch A14 was carried out at 400 C in a humidity 
jar having 75 % RH according to ICH(7). Samples 
were withdrawn after three month and evaluated 
for change in buoyancy characteristics and drug 
release pattern. The similarity factor (f2) was 
applied to study the effect of storage on batch 
A14. 
 
Results and Discussion 
From preliminary investigation it was found that 
the ratio of HPMC K4 M to HPMC K100LV and 
addition of citric acid had desirable influence on 
drug release. Therefore, the influence of the ratio 
of HPMC K4M to HPMC K100LV and content 
of citric acid on drug release from floating matrix 
tablets was studied using 32 full factorial design. 
The results of evaluation of tablets of factorial 
design batches are depicted in Table 2. Tablets of 
each batch had complied the assay, weight  
variation and friability test according to USP 28 
.Tablets of each batch had floating lag time below 
2 min in (55 sec to 118 sec) regardless of ratio  
HPMC K4M to HPMC K100 LV and content of 
citric acid. Tablets  of each batch constantly 
floated on dissolution medium for more than 12 
hr except  the  tablets of batch A11 which might 
be due to lower strength of hydrophilic matrices 
as well as presence of citric acid increased the 
influx of dissolution  medium subsequently leads 
to weakening of the strength of the matrices. 
 
From the results of in vitro drug release studies 
(Figure 5) it was found  that addition of more 
amount of lower viscosity grade of HPMC   at all 
levels of content of citric acid, the drug release 
was increased  might be due to the lowering of 
the viscosity of the hydrophilic matrices which 
opened up the channels for faster penetration of 
dissolution medium inside the swelled matrices 
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leads to more availability of fresh dissolution 
medium inside the matrix leads to increased  
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Figure 6.   Influence of fraction of HPMC K100LV on diffusion exponent at   Citric 
acid (a) 2 % (b) 1% and (c) 0% and on release rate constant at Citric acid (d) 2 % (e) 
1% and (f) 0% 
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dissolution of un-dissolved particle of the drug 
and it may leads to increased  in diffusion of drug 
out of the matrices due to weaker gel layer 
formed. It was observed that addition of citric 
acid improved the drug release at 1% of total 
tablet weight compared to tablets without citric 
acid but further increase in content of citric acid 
to 2 % of total tablet weight did not gave 
significant improvement in drug release in tablets 
containing higher fraction of HPMC K100LV 
might be due the attainment of agglomeration at 
higher level which may entrapped the molecule 
of drug inside the agglomeration formed. 
 
The difference in drug  release was observed 
when content of citric acid was increased from 
0% to 2% in tablets containing lower  proportion 
of HPMC K100LV  might be due to masking of 
influence of addition of  HPMC K100LV  in 
lower amount  which was not observed at higher 
proportion of  HPMC K100LV might be due to 
more contribution of  lower viscosity of HPMC  
in increasing drug release . So it was cleared that 
the addition of HPMC K100LV had dominant 
influence on drug release compared to citric acid. 
It was observed that the change in drug release 
profile was more significant when the proportion 
of HPMC K100LV was increased compared to 
change in content of citric acid. 
 
The results of t50%, Q12, release rate constant (k) 
and diffusion exponent (n) showed wide variation 
(Table 3). The data clearly indicate that the 
dependent variables are strongly dependent on 
independent variables. The value of the 
correlation co-efficient indicates a good fit.  
Results of multiple regression analysis were 
shown that the ratio of HPMC K4M to HPMC 
K100LV and content of citric acid had significant 
influence for time required for 50% of drug 
release (P < 0.05, Table 3.15). For factor X1, it 
was found that there is a statistically significant 
difference between 1 and -1 level, (P<0.05). For 
factor X2, it was found that there is statistically 
significant difference between level 0 and -1 (P < 
0.05). From results it was cleared that release rate 
was higher at citric acid concentration of 1% 
compared to 2% and without citric acid; which 
might be due to solubilization effect of citric acid 
at 1 % level which was not observed with 2 % 
due to chances of micelle formation inside which 
drug was entrapped and rate of drug release was 
decreased. For percentage drug at 12 hr, it was 
found that the ratio of HPMC K4M to HPMC 
K100 LV and content of citric acid had 
significant influence (P < 0.05). From results of 
Tukey test it was observed that for X1 there is 
significant difference was observed between 
levels of 0 and 1 as well as 1 and -1 indicate 
fraction of HPMC K100LV higher levels 
significantly contributed for Q12, while for X2 
only the difference observed significantly 
between 0 and -1 levels indicate content of citric 
acid above 1 % do not significantly contributed 
for Q12. 
 
There has been considerable interest in using 
different grades of HPMC in controlled release 
drug delivery system due to their hydrophilic 
nature and fast hydration.(8) The release profiles 
appear to be bi-phasic with initial burst effect 
followed by a polymer-controlled slower release 
in the second phase. The difference in burst effect 
of the initial time is a result of difference in the 
viscosity of the polymeric mixtures (9) as well as 
amount of citric acid which mainly contribute in 
dissolution of drug in initial period. The 
polymeric system with higher content of HPMC 
K100LV yielded a faster initial burst effect. 
Dortunc and Gunal have reported that increased 
viscosity resulted in a corresponding decrease in 
the drug release which might be due to thicker gel 
layer formation. On other hand, the apparent drug 
release rate observed in the second phase from 
different polymeric mixture are quite similar 
which describe that once the gel layer formed, 
there appears  to be no difference in release rate. 
Diffusion exponent ranges from 0.242 to 0.490, 
while release rate constant ranges from 20.39 to 
60.24, which indicate independent variables, had 
significant effect on mechanism and kinetics of 
drug release. Both variables significantly affect 
the release rate constant and diffusion exponent 
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(P<0.05). Linear relationship was obtained 
between faction of HPMC K100 LV and 
diffusion exponent and it was observed that as 
fraction of HPMC K100LV increased the value 
of diffusion exponent is decreased (Figure 6) at 
all the three levels of citric acid and release 
mechanism changes from anomalous transport to 
case-I transport, which might be due to 
dominance of chain disentanglement leads to 
chain relaxation and subsequent dissolution of 
polymer. The similar phenomenon was also 
observed in case or release rate constant. Linear 
relationship was obtained between fraction of 
HPMC K100 LV and release rate constant. It was 
observed that as the  fraction of HPMC K100 LV 
increases, the rate of drug release was also 
increased at all the three levels of citric acid 
which might be due to lowering of viscosity of 
polymeric mixtures (Figure 6).  
 
Conclusion 
For the development of controlled release dosage 
form for poorly soluble drug like Cefixime 
trihydrate, polymer blends of different viscosity 
grade of HPMC and presence of citric acid 
appears necessary, which imparts hydrophilic 
environment and to increase drug release, 
respectively .Tablets had desired buoyancy 
characteristics. It was found that ratio of HPMC 
K4M to HPMC K100LV  had dominant role on 
drug release  from floating matrix tablets 
compared to citric acid, although the presence of 
later  component in formulation with optimum 
concentration is essential to improve the drug 
release of hydrophobic molecules of drug. The 
promising formulation (Batch A14) had desire 
drug release kinetics and found to be stable for 3 
months under stability study. 
 
 
Acknowledgments 
The authors are thankful to Lincoln 
Pharmaceuticals Limited, Ahmedabad, India, for 
providing gift samples of Cefixime and to Zydus 
Cadila Healthcare Limited, Ahmedabad, India, 
for providing various grades of HPMC. 
 
References 
1. Kees F, Lukassek U, Naber KG, 
Grobecker, H. Comparative investigations 
on the bioavailability of cefuroxime 
axetil. Drug Res. 1991; 41: 843-846. 
2. Goodman and Gilman’s The 
pharmacological Basis of therapeutics. 
Eleventh edition. McGraw-Hill: Medical 
publishing division; 1807. 
3. Yeole PG, Khan S, Patel VF. Floating 
drug delivery systems: Need and 
development. Indian. J. Pharm. Sci. 2005; 
67: 265-272. 
4. US pharmacopoeia 28. United state 
Pharmacopoeial convention. Rockville 
MD. USA. Asian edition, 2005; 2509. 
5. US pharmacopoeia 28. United State 
Pharmacopoeial convention. Rockville, 
MD. USA. Asian edition, 2005;2745. 
6. Patel VF, Patel NM, Yeole PG. Studies on 
formulation and evaluation of ranitidine 
floating tablets. Indian J. Pharm. Sci. 
2005; 67: 703-709. 
7. Carstensen JT, Drug stability: Principle 
and practices. Marcal Dekker. New York, 
USA, 2nd ed. 1995, 538-550. 
8. Colombo P, Bettini R, Peppas NA. 
Observation of swelling process and 
diffusion front position during swelling in 
HPMC matrices containing soluble drug. 
J. Control Release. 1999; 61: 83-91. 
9. Dow Chemical Co., Methocel: Cellulose 
ethers technical handbook. 1996; 18-20. 
10. Costa, P., An alternative method to 
evaluation of similarity factor in 
dissolution testing. Int. J. Pharm., 220, 
2001, 77-83. 
11. Moore, J. W. and Flanner, H. H., 
Mathematical comparison of dissolution 
profiles, Pharm. Technol. 20(6), 1996, 67-
74. 
 
